Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company AbbVie (ABBV 1.85%) has earned a coveted five-star ranking.
With that in mind, let's take a closer look at AbbVie and see what CAPS investors are saying about the stock right now.
AbbVie facts
|
Headquarters (Founded) |
North Chicago, Ill. (2012) |
|
Market Cap |
$72 billion |
|
Industry |
Pharmaceuticals |
|
Trailing-12-Month Revenue |
$18.5 billion |
|
Management |
Chairman/CEO Richard Gonzalez |
|
Trailing-12-Month Return on Equity |
71.4% |
|
Cash/Debt |
$7.5 billion / $15.2 billion |
|
Dividend Yield |
3.5% |
|
Competitors |
Gilead Sciences |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 97% of the 151 members who have rated AbbVie believe the stock will outperform the S&P 500 going forward.
Just last week, one of those Fools, cschweit, tried to calm a few concerns surrounding the AbbVie opportunity:
This stock will be quite [volatile] for the next few years, but its pipeline is strong. ... 2016 is the "big" year according to many analysts because of Humira patent protection loss, but this is an overhyped notion based on trends in the pharmaceutical market in general, not specifically based on the type of product it is. ... The "patent cliff" is typically more important when it comes to small molecule drugs because generics are much easier to develop for these types of medicines. ... The next few years will be crucial, though, for this young company -- especially with the race with [Gilead] over Hepatitis C medicines.
